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Available online 12 October 2017The effects of zoledronic acid on hip structural and biomechanical properties were evaluated in Japanese patients
with osteoporosis by computed tomography (CT).
The subjects included in this study were a subset of female subjects (zoledronic acid group, 49 subjects; placebo
group, 53 subjects) in the phase 3 trial (ZONE study)whowere available formulti-detector rowCT (MDCT) scan-
ning. Eligible subjects were those diagnosed with primary osteoporosis based on the Diagnostic Criteria for Pri-
mary Osteoporosis (2000) by the Japanese Society for Bone and Mineral Research and who had between one
and four fractured vertebrae located between the fourth thoracic vertebra and the fourth lumbar vertebra. The
subjects received a once-yearly intravenous infusion of zoledronic acid 5 mg or placebo for two years. CT data
were obtained at baseline and at 12 and 24 months later and analyzed under blinded conditions.
The results demonstrated that once-yearly intravenous infusion of zoledronic acid improved volumetric bone
mineral density (vBMD), cortical bone geometry parameters, and CT-derived biomechanical parameters at the
femoral neck, intertrochanteric region, and shaft; particularly at the intertrochanteric region, significant im-
provements in cortical bone geometry parameters and CT-derived biomechanical parameters, compared with
those in the placebo group, were detectable early, at 12 months. The present data suggest that zoledronic acid








Zoledronic acid is known to have a powerful inhibitory effect on
bone resorption when infused intravenously once yearly, an interval
of administration that is the longest among injectable bisphosphonates
for the treatment of osteoporosis. An international multi-institutional
clinical trial (Health Outcomes and Reduced Incidence with Zoledronic
acid ONce yearly Pivotal Fracture Trial [HORIZON-PFT]) involving
N7000 subjects demonstrated that 3-year treatment with zoledronic
acid reduced new vertebral fractures by 70% and hip fractures by 41%
and increased lumbar bone mineral density (BMD) from baseline by
6.71%, hip BMD by 6.02%, and femoral neck BMD by 5.06% compared
with placebo [1]. A phase 3 trial of zoledronic acid (ZOledroNate treat-
ment in Efficacy to osteoporosis [ZONE] study) in Japanese subjects
also demonstrated that 2-year treatment increased lumbar BMD bypen access article under7.61%, hip BMD by 4.03%, and femoral neck BMD by 4.07%, and reduced
new vertebral fractures by 66% compared with placebo. Furthermore,
for the first time in a study of an osteoporosis drug in Japan, zoledronic
acid significantly reduced nonvertebral fractures (45%, compared with
placebo) [2].
Noninvasive methods for evaluating the effect of an osteoporosis
drug on improving bone biomechanical parameters, which may serve
as surrogate markers of bone strength, have been established. One
such method has allowed studies conducted in recent years to evaluate
bone biomechanical properties from bone structural properties using
images. In particular, 3-dimensional visualization of bone structure by
computed tomography (CT) has been used for morphological quantifi-
cation. Thus, even for the femur, which has a complicated structure,
the cross-sections that intersect the axis of the femoral neck or shaft
can be precisely extracted. Additionally, the femur can be further divid-
ed into the neck, the intertrochanteric region, and the shaft areas, and,
in each of these areas, the cortical bone can be extracted for evaluations
that yield detailed information on cortical bone structural propertiesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1





Age (years) 74.3 ± 5.6 72.6 ± 5.2
Body height (cm) 147.86 ± 6.85 149.37 ± 5.12
Weight (kg) 51.41 ± 8.16 52.65 ± 9.09
Body mass index (BMI) (kg/m2) 23.53 ± 3.50 23.58 ± 3.72
Years after menopause (years) 23.9 ± 6.2 21.7 ± 6.4
Bone mineral density (T-score)
Lumbar spine (L1–4) −2.968 ± 0.725 −3.049 ± 0.875
Femoral neck −3.086 ± 0.946 −3.136 ± 0.779
Femoral total hip −2.428 ± 0.961 −2.429 ± 0.879
Number of prevalent vertebral fractures 1.4 ± 0.9 1.4 ± 0.9
Bone mineral density was measured by dual X-ray absorptiometry.
Data are means ± SD.
180 M. Ito et al. / Bone 106 (2018) 179–186[3–6]. In addition, by matching 3-dimensional CT images taken before
and after treatment, CT images of the same site can be extracted and
compared over time.
While there have been reports of bone structural evaluations by CT
of the effects of active vitamin D [7] and teriparatide [8,9], to the best
of our knowledge, there have been no reports of detailed evaluations
by clinical CT of the effects of bisphosphonates on femoral cortical ge-
ometry and bone mineral density in Japanese subjects. Given that
bisphosphonates have a different tissue level mechanism of action
than active vitamin D and teriparatide, zoledronic acid may have a dif-
ferent effect on bone structural properties than these drugs do. There-
fore, analysis of CT geometry was used to evaluate the effects of
zoledronic acid on bone structural properties in Japanese osteoporosis
patients who were enrolled in the ZONE study.Table 2
Baseline QCT measurements and percent changes at 12 and 24 months.
Region Parameter Zoledronic acid (N = 49)
Baseline Percen
12 mon
Femoral neck Cortical thickness (mm) 1.64 ± 0.32 2.43 ±
Cortical CSA (cm2) 0.97 ± 0.17 1.12 ±
Total CSA (cm2) 1.33 ± 0.20 0.27 ±
Cortical perimeter (cm) 11.01 ± 0.90 −1.56
Cortical vBMD (mg/cm3) 663.46 ± 41.99 0.25 ±
Total vBMD (mg/cm3) 235.93 ± 40.22 1.25 ±
CSMI (cm4) 0.58 ± 0.16 0.94 ±
SM (cm3) 0.42 ± 0.11 1.48 ±
BR 12.43 ± 3.16 −2.63
Femoral intertrochanteric region Cortical thickness (mm) 1.51 ± 0.26 4.74 ±
Cortical CSA (cm2) 1.54 ± 0.29 3.74 ±
Total CSA (cm2) 2.59 ± 0.38 2.95 ±
Cortical perimeter (cm) 17.32 ± 1.25 −0.15
Cortical vBMD (mg/cm3) 641.26 ± 43.08 −0.39
Total vBMD (mg/cm3) 194.29 ± 36.90 3.11 ±
CSMI (cm4) 1.67 ± 0.59 6.59 ±
SM (cm3) 0.81 ± 0.25 4.78 ±
BR 19.63 ± 4.07 −5.83
Femoral shaft Cortical thickness (mm) 3.95 ± 0.56 1.78 ±
Cortical CSA (cm2) 2.37 ± 0.30 1.62 ±
Total CSA (cm2) 2.54 ± 0.29 1.20 ±
Cortical perimeter (cm) 10.48 ± 0.75 −0.84
Cortical vBMD (mg/cm3) 890.87 ± 70.60 1.55 ±
Total vBMD (mg/cm3) 481.19 ± 80.08 2.83 ±
CSMI (cm4) 1.26 ± 0.31 1.03 ±
SM (cm3) 0.97 ± 0.18 1.73 ±
BR 3.37 ± 0.74 −1.75
Data are means ± SD.
QCT, quantitative computed tomography; CSA, cross-sectional area; vBMD, volumetric bonemi
ratio, Cortical perimeter; Periosteal cortical perimeter.
⁎ p b 0.05.
⁎⁎ p b 0.01 compared with baseline by paired t-test.2. Subjects and methods
2.1. Subjects
The subjects in this study were a subset of female subjects in the
ZONE study [2]whowere available for CT scans. These subjectswere en-
rolled at one of 17 sites with a multi-detector row computed tomogra-
phy (MDCT) scanner capable of measuring femoral geometry. Patients
eligible for the ZONE study were those diagnosed with primary osteo-
porosis based on the Diagnostic Criteria for Primary Osteoporosis
(2000) by the Japanese Society for Bone and Mineral Research. In
short, if a patient had a BMD of b80% of young adult mean (YAM), or
possible osteoporosis on radiographic images and a previous history of
fragility fracture, the patient was diagnosed as having primary osteopo-
rosis. In a patient with no previous history of fragility fracture, if the
BMD was b70% of YAM or osteoporosis was observed on radiographs,
the patientwas diagnosed as having primary osteoporosis [10]. Patients
whohad between one and four fractured vertebrae located between the
fourth thoracic vertebra and the fourth lumbar vertebra were also in-
cluded. The following subjectswere excluded: patientswith any disease
or taking any medication that affects bone metabolism; and subjects
with decreased renal function who met the criterion for decreased
renal function defined as an increase in the serum creatinine level of
N0.5 mg/dL during the pretreatment observation period or a creatinine
clearance of b35.0 mL/min calculated from the Cockcroft and Gault for-
mula or a urine protein level of 2+ormore at the time of informed con-
sent or on the first day of treatment.
The subjects were randomized into two groups to receive once-
yearly intravenous infusions of zoledronic acid 5 mg or placebo over
15min for two years. All subjects also received daily supplements of cal-
cium 610 mg, vitamin D3 400 IU, and magnesium 30 mg. The ZONE
study was conducted according to the ethical principles of thePlacebo (N = 53)
t change (%) Baseline Percent change (%)
ths 24 months 12 months 24 months
5.93⁎⁎ 4.09 ± 8.12⁎⁎ 1.58 ± 0.26 1.67 ± 9.32 0.52 ± 7.06
5.85 2.59 ± 7.70 0.94 ± 0.17 1.13 ± 9.00 −2.57 ± 5.00⁎⁎
3.91 1.37 ± 5.33 1.31 ± 0.19 0.82 ± 6.57 −1.89 ± 3.58⁎⁎
± 5.44 −1.41 ± 6.74 11.04 ± 0.87 −0.57 ± 5.86 −2.27 ± 5.21⁎⁎
3.01 1.08 ± 3.05⁎ 670.78 ± 45.95 0.52 ± 3.86 −0.27 ± 2.37
4.52 2.44 ± 4.11⁎⁎ 234.40 ± 36.90 0.46 ± 4.67 −0.93 ± 4.48
8.55 0.55 ± 12.67 0.57 ± 0.15 −0.20 ± 11.61 −6.71 ± 8.51⁎⁎
7.14 1.79 ± 11.46 0.41 ± 0.10 −0.54 ± 10.51 −4.75 ± 8.84⁎⁎
± 6.91⁎ −3.28 ± 8.87⁎ 13.04 ± 3.19 −0.79 ± 9.49 −1.09 ± 7.99
8.29⁎⁎ 2.98 ± 6.17⁎⁎ 1.50 ± 0.28 −0.52 ± 7.58 −1.67 ± 7.50
6.90⁎⁎ 3.87 ± 5.00⁎⁎ 1.52 ± 0.31 −0.60 ± 6.25 −2.63 ± 6.92⁎
5.35⁎⁎ 2.33 ± 6.00⁎ 2.57 ± 0.49 0.37 ± 7.83 −2.96 ± 7.51⁎
± 3.60 −0.56 ± 4.18 17.19 ± 1.17 0.67 ± 3.67 −1.01 ± 4.13
± 2.14 0.30 ± 2.14 633.80 ± 40.52 0.41 ± 3.30 0.72 ± 2.35
5.07⁎⁎ 2.75 ± 5.54⁎⁎ 192.01 ± 32.23 −0.54 ± 6.40 −2.03 ± 6.27⁎
15.98⁎⁎ 3.57 ± 17.38 1.72 ± 0.59 −0.71 ± 17.22 −9.21 ± 15.77⁎⁎
14.92⁎ 4.16 ± 17.25 0.83 ± 0.25 −0.16 ± 16.29 −8.47 ± 14.48⁎⁎
± 8.61⁎⁎ −2.79 ± 7.53⁎ 19.52 ± 3.98 2.79 ± 12.40 3.74 ± 10.30⁎
4.98⁎ 0.81 ± 3.79 3.92 ± 0.61 −0.21 ± 5.18 −2.79 ± 4.89⁎⁎
3.45⁎⁎ 1.48 ± 2.76⁎⁎ 2.33 ± 0.36 0.29 ± 3.50 −0.95 ± 3.12
3.01⁎⁎ 1.29 ± 2.38⁎⁎ 2.49 ± 0.35 0.12 ± 2.80 −0.67 ± 2.62
± 3.93 −1.34 ± 4.30 10.41 ± 0.67 −0.29 ± 5.49 1.31 ± 5.50
3.47⁎⁎ 1.29 ± 3.13⁎ 888.05 ± 58.31 0.28 ± 3.79 −0.72 ± 3.21
5.72⁎⁎ 2.11 ± 4.65⁎ 477.68 ± 73.91 0.59 ± 6.13 −1.65 ± 5.98
7.49 3.27 ± 6.08⁎⁎ 1.24 ± 0.24 0.36 ± 4.15 0.74 ± 3.98
5.88⁎ 2.95 ± 5.98⁎⁎ 0.96 ± 0.16 −0.18 ± 5.33 −0.62 ± 4.30
± 6.66 −0.07 ± 4.84 3.39 ± 0.75 0.49 ± 7.87 4.56 ± 7.81⁎⁎
neral density; CSMI, cross-sectional moment of inertia; SM, section modulus; BR, buckling
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(GCP). The institutional review board (IRB) at each site approved the
protocol in advance, and all subjects provided written, informed con-
sent before enrollment.
2.2. CT data acquisition
CT datawere obtained using the scanning and reconstruction proto-
col reported previously at baseline and at 12 and 24 months [11]. The
scanning method (X-ray energy, 120 kV; X-ray current, 250 mA; rota-
tion speed, 0.5–0.7 s/rotation; beam pitch, 0.5625–0.938) and the re-
construction parameters were evaluated and determined in advance
for each type of CT. Beam pitch is specified as the ratio of table feed
per rotation to collimation (slice collimation), which is determined by
the slice-thickness and the number of slices in each rotation. Field of
view (FOV) was defined as 350 mm to cover bilateral femoral neck
regions.
The x-y plane spatial resolution (0.625–0.652 mm) and the recon-
structed slice thickness (0.500–0.625 mm) were adjusted dependingFig. 1.Mean percent changes and 95% confidence interval from baseline in cortical thickness (
(d) at 12 months and 24 months with zoledronic acid and placebo. Changes at the femoral ne
panel indicate p-values between zoledronic acid and placebo. To compare the differences betw
by Student's t-test.on the CT scanner type. CTmeasurements were converted to bonemin-
eral scale using a reference phantom B-MAS200 (FUJIREBIO Inc., Tokyo,
Japan) containing hydroxyapatite (HA) at 0, 50, 100, 150, and
200 mg/cm3.
The MDCT scanners used in this study were: Activision 16 at one
study site, Activision TM 16 at two, Aquilion 16 at three, Aquilion
64 at one, Aquilion CXL at one, Asterion Super 4 Edition scanners
(Toshiba Medical Systems Corporation, Otawara, Japan) at one,
LightSpeed Ultra at one, LightSpeed VCT 64 at one, LightSpeed VCT VI-
SION at one, BrightSpeed SD 16ch at one, OptimaCT 660 scanner (GE
Yokogawa Medical, Hino, Japan) at one, Somatom Sensation 16 at two,
and Somatom Definition AS + scanner (Siemens AG, Munich,
Germany) at one. Basically, a subject was scanned using the same CT
scanner throughout the study period, but one of the study sites that
used the Somatom Sensation 16 switched to a different model, Aquilion
64 TSX-101A scanner (ToshibaMedical Systems Corporation), for taking
measurements midway through the study. The quality control (QC)
data were checked before and after the switch with a Type 3 Mindways
Phantom (Mindways Software, Austin, TX, USA).a), cortical cross-sectional area (CSA) (b), total CSA (c), and periosteal cortical perimeter
ck, femoral intertrochanteric region, and femoral shaft are shown. Values on top of each
een the two groups, the percent changes from baseline in QCT parameters were compared
182 M. Ito et al. / Bone 106 (2018) 179–1862.3. Quality assurance of scanners
All CT scanners gave good positive linear correlations between CT
values and HA concentrations (r = 0.994–1.000; p b 0.0001). Differ-
ences in CT values due to X-ray energy fluctuations were corrected
using a phantom to convert CT values to HA values. To correct changes
in the detector over the long-term, reliability assurance with a Type 3
Mindways Phantom (Mindways Software) was performed before and
after measurements at each of the medical institutions. The reliability-
assurance measurements were conducted in accordance with
Mindways' QCT-Pro QA Guide. No changes in performance characteris-
tics were noted with any of the CT scanners between baseline and com-
pletion of treatment.
2.4. Subject positioning for CT scanning
The femur of each of the subjectswas scanned from the top of the ac-
etabulum to 4 cm below the bottom of the lesser trochanter with the
subject in a supine position and the phantom placed underneath the
subject (mean number of slices, 350). A cushioning material such as a
bolus bag or blanket was placed between the subject and the phantom
to prevent artifacts, and the subject's hands and arms were positioned
overhead or higher than the chest to avoid any impacts on the scan
area. The CT scanner table height was set to the center of the greater
trochanter.
2.5. Analyses of BMD, bone geometry, and biomechanical parameters ob-
tained by CT
The subjects' femoral neck, intertrochanteric region, and shaft data
were evaluatedwith QCT-Pro software v4.1.3with theQCT-Pro Bone In-
vestigational Toolkit v2.0 (BIT) (Mindways Software). All measurement
data were analyzed by a single radiologist who was blinded to the case
information.
2.6. QCT-Pro CTXA femoral neck analysis
Using the eccentricity registration method, a series of six consecu-
tive 1-mm slices were placed vertically to the neck axis. The definitions
of intertrochanteric region and shaft cross-sections were identical toFig. 2.Mean percent changes and 95% confidence interval from baseline in cortical volumetric
zoledronic acid and placebo. Changes at the femoral neck, femoral intertrochanteric region
zoledronic acid and placebo. To compare differences between the two groups, the percent chathose in the dual energy X-ray absorptiometry (DXA)-based hip struc-
ture analysis (HSA) developed by Beck [12]. All images acquired from
a subject during the study period were compared visually andmatched.
In the eccentricity registrationmethod, the area consisting of six consec-
utive 1-mm slices of the image oriented perpendicular to the neck axis
was defined as a 3-dimensional region of interest. The QCT BIT process-
ing was performed with a fixed threshold for determining the cortical
margin set to 350mg/cm3 for all subjects andmeasurements. This appli-
cation was used to measure volumetric BMD (vBMD) and cross-
sectional area (CSA) and cross-sectional bone mass of the femoral
neck, intertrochanteric region, and shaft (total and cortical bone area),
as well as cortical thickness and periosteal cortical perimeter. Bone bio-
mechanical parameters were also calculated from the cross-sectional
parameters of the femoral neck, intertrochanteric region, and shaft
with the QCT-Pro software.2.7. Analysis of cross-sectional area, vBMD, and bone mass
The cortical CSA (cm2), total CSA (cm2), cortical vBMD (mg/cm3),
total vBMD (mg/cm3), total bonemass (g), cortical bonemass (g), thick-
ness (mm), and periosteal cortical perimeter (cm) were calculated
based on the cross-sectional data for the femoral neck, intertrochanteric
region, and shaft. The CSA was determined from the estimated total
mineralization area.2.8. Bone biomechanical parameters
Biomechanical parameters including the cross-sectional moment of
inertia (CSMI; cm4), the sectional modulus (SM; cm4), and the buckling
ratio (BR) were calculated. The CSMI was calculated by integration of
the CSA of the mineralized cortical bone and the square of the distance
from the center of mass (centroid). The SM is the ratio of CSMI to the
maximal distance from the centroid, which is an index correlated to
bending strength. The local BR was calculated by dividing the maximal
distance from the centroid with the cortical thickness, which is an
index of structural stability [12].
The reproducibility of the analysis by the QCT-Pro program was re-
ported previously [8].bone mineral density (vBMD) (a) and total vBMD (b) at 12 months and 24 months with
, and femoral shaft are shown. Values on top of each panel indicate p-values between
nges from baseline in QCT parameters were compared by Student's t-test.
183M. Ito et al. / Bone 106 (2018) 179–1862.9. Statistics
All statistical analyses were performed on subjects who had been
randomized and had completed the QCT evaluations at baseline and at
12 and 24 months. The methods used included Student's t-tests for
comparing the zoledronic acid groupwith the placebo group for percent
change from baseline and paired t-tests for comparing baseline values
with those at 12 or 24 months. The p values were two-sided, without
multiplicity adjustment. Statistical analyses were performed with SAS
version 9.4 (SAS Institute, Cary, NC, USA).
3. Results
3.1. Subject demographics and baseline bone characteristics
The subject demographics and baseline bone characteristics for each
group are shown in Table 1. In the ZONE study, 112 (8male subjects and
104 female subjects) of the 665 subjects administered zoledronic acid or
placebo underwent QCT scans. All subjects in the analysis in the present
study were female, including 49 in the zoledronic acid group and 53 in
the placebo group. There were no significant differences between theFig. 3. Mean percent changes and 95% confidence interval from baseline in cross-sectional m
12 months and 24 months with zoledronic acid and placebo. Changes at the femoral neck, fem
indicate p-values between zoledronic acid and placebo. To compare the differences between t
Student's t-test.two groups in age, height, weight, body mass index (BMI), years after
menopause, BMD at the lumbar spine and proximal femur, and the
number of vertebral fractures. The baseline characteristics (age, height,
weight, BMI, menopausal age, and T-score) of the subjects of this study
were similar to those of the ZONE study [2]; thus, the population was
representative of the population of the ZONE study.
3.2. Effects of zoledronic acid on changes from baseline in various
parameters
The baseline and percent changes (%) at 12 and 24 months for QCT
parameters from baseline are shown in Table 2. There were no remark-
able differences at baseline for any parameter at the femoral neck,
intertrochanteric region, and shaft between the zoledronic acid and pla-
cebo groups.
In summary, compared with baseline, once-yearly treatment with
zoledronic acid significantly improved: cortical thickness at the neck
and intertrochanteric region; cortical CSA and total CSA at the
intertrochanteric region and shaft; total vBMD at all sites; cortical
vBMD at the neck and shaft; SM and CSMI at the shaft; and BR at the
intertrochanteric region and neck. Therewere no changes from baselineoment of inertia (CSMI) (a), section modulus (SM) (b), and buckling ratio (BR) (c) at
oral intertrochanteric region, and femoral shaft are shown. Values on top of each panel
he two groups, the percent changes from baseline in QCT parameters were compared by
184 M. Ito et al. / Bone 106 (2018) 179–186in the periosteal cortical perimeter at any site in the zoledronic acid
group.
3.3. Effects of zoledronic acid treatment on cortical bone geometry com-
pared with placebo
Percent changes from baseline in cortical thickness, cortical CSA,
total CSA, and periosteal cortical perimeter are shown in Fig. 1.
In summary, cortical thickness, cortical CSA, and total CSA were sig-
nificantly higher at all sites in the zoledronic acid group than in the pla-
cebo group at 24 months.
3.4. Effects of zoledronic acid on vBMD compared with placebo
Percent changes from baseline in cortical vBMD and total vBMD are
shown in Fig. 2.
In summary, total vBMD in the zoledronic acid group was signifi-
cantly higher at all sites at 24months, and cortical vBMDwas also signif-
icantly higher at the femoral neck and shaft than in the placebo group at
24 months.
3.5. Effects of zoledronic acid on CT-derived bone biomechanical parame-
ters compared with placebo
Percent changes from baseline in CSMI, SM, and BR are shown in
Fig. 3.Fig. 4. Schematic illustration of the effects of zoledronic acid on cortical geometry and density
black in the periphery indicates a higher vBMD. SM: section modulus, BR: buckling ratio. The
on the previous paper [8].In summary, CSMI and SM were significantly higher at all sites at
24 months, and BR was significantly lower at the femoral
intertrochanteric region and shaft in the zoledronic acid group than in
the placebo group at 24 months.
4. Discussion
This study evaluated the effects of 2-year treatment with once-
yearly intravenous infusions of zoledronic acid on femoral cortical
bone geometry, vBMD, and CT-derived biomechanical parameters in a
subset of 102 female subjects in the ZONE study, which was conducted
in Japanese patients with osteoporosis. This is the first CT assessment of
the effect of bisphosphonates on hip geometry in Japanese female sub-
jects. Data from this study demonstrated that once-yearly intravenous
infusions of zoledronic acid improved vBMD, cortical bone geometry pa-
rameters, and CT-derived biomechanical parameters at the femoral
neck, intertrochanteric region, and shaft; particularly at the
intertrochanteric region, improvements in cortical bone geometry pa-
rameters and biomechanical parameters, compared with those in the
placebo group, were already significant at 12 months.
In this study, higher total vBMD was observed at the femoral neck,
intertrochanteric region, and shaft in the zoledronic acid group com-
paredwith the placebo group. Similarly, the vBMDevaluation byCTper-
formed in the HORIZON-PFT study showed significantly higher integral
vBMD at the femoral neck and intertrochanteric region at 36 months
(total 230 subjects) [13]. An examination of the effect on cortical
vBMD showed no difference between the zoledronic acid and placeboof the femoral neck, intertrochanteric region, and shaft, compared to placebo. The darker
effect of once-weekly teriparatide treatment on the proximal femur is illustrated based
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icantly higher cortical vBMD was observed in the neck and shaft at
24 months. While it is difficult to make a comparison between the
HORIZON-PFT study and the ZONE study due to the use of different an-
alytical programs and differences in imaging conditions and subject de-
mographics, the ZONE study demonstrated the effect of 2-year
treatment with zoledronic acid in significantly increasing cortical
vBMD at the femoral neck and shaft, but the increasewas not significant
at the intertrochanteric region. This discrepancy among bone sites may
be attributable to the effect of zoledronic acid on reduction in cortical
porosity [14]. Increases of cortical vBMD are readily detectable in the
neck and shaft, which is thick in cortical bone, and changes in cortical
vBMD are difficult to detect by CT in the intertrochanteric region,
which is thin in cortical bone.
A comparison was made with the results of studies on the effects of
bisphosphonates on hip geometry. The effects of monthly ibandronate
on the geometric properties of the hip were evaluated by DXA-based
HSA in 89 Caucasian men with low BMD and compared with placebo,
and the study demonstrated that cortical thickness, CSA, SM, and BR
were significantly improved in the femoral intertrochanteric region
and shaft compared with placebo, but the difference was not significant
in the narrow neck [15]. The results of this study in Caucasian subjects
were similar to those of the present study in terms of the effects on
structural characteristics, although there was a difference in whether
the effect was significant.
There has been one study that evaluated vBMD and bone geometry
properties with CT in a similar manner in a subset of subjects who re-
ceived once-weekly teriparatide in the TOWER trial [8]. The once-
weekly teriparatide treatment for 72 weeks was shown to improve cor-
tical thickness, cortical CSA, and CT-derived bone biomechanical param-
eters compared with placebo treatment. Moreover, as a result of
teriparatide treatment, total vBMD remained at or increased from the
baseline level, while cortical vBMD decreased slightly. This shows that
the once-weekly teriparatide treatment had an effect in maintaining
the bone perimeter while increasing Haversian remodeling and cortical
porosity, or lowering the material density, or both, in the inner cortical
region, suggesting that bone strength improves in associationwith such
a process [8]. Both teriparatide and bisphosphonates improve bone bio-
mechanical properties, but by different tissue level mechanisms of ac-
tion. As a result, their effects on vBMD and bone geometry are also
different (Fig. 4). In other words, the structural properties analyzed
based on CT indicated that the two agents have different effects on the
cortical bone; while teriparatide increases cortical and trabecular bone
volume to improve bone strength, zoledronic acid prevents thinning
of the cortex, decreases the rate of remodeling, and reduces cortical po-
rosity, thus acting differently to improve bone strength.
Moreover, in the intertrochanteric region, despite significant in-
creases from baseline in cortical CSA with both zoledronic acid and
teriparatide, a difference in cortical thickness was noted: no change in
cortical thicknesswas detectedwith teriparatide treatment, but the cor-
tical thickness increased significantly at 12monthswith zoledronic acid
treatment. Such a difference ismainly attributable to thedifficulty in de-
tecting changes in the cortical bone of the intertrochanteric region due
to the thinness of the cortical bone. With teriparatide, the new cortical
bone formed at the endocortical surfacewas poorlymineralized and po-
rous andwas not perceived as an increased cortical thickness on CT [16].
With zoledronic acid, on the other hand, the cortical bone thicknesswas
preserved or increased as a result of suppression of excessive bone
resorption.
Although the comparison between the two drugs used results de-
rived from different studies rather than a study that directly compared
the drugs' effects, the difference in bone structural change described
abovemay be reflected by a difference in effect between a bone resorp-
tion inhibitor and a bone formation stimulator.
The ZONE study in Japanese patients with osteoporosis did not dem-
onstrate an inhibitory effect on hip fractures because it was conductedin a small number of subjects over a short study period (total 665 sub-
jects joined, 2-year study), and none of the subjects assessed in this
QCT study suffered any femoral fractures during the study period. A
large-scale international clinical trial of zoledronic acid in patients
with osteoporosis, however, demonstrated that zoledronic acid signifi-
cantly reduced the risk of hip fractures [1]. Furthermore, the previous
study of CT-based hip structure analysis compared the characteristics
of vBMD and bone geometry of the femoral neck. The comparison be-
tween subjects with hip fracture and age/sex-matched subjects with
no fracture showed the following risk factors: low total vBMD, cortical
vBMD, cortical CSA, cortical thickness, and CSMI for both femoral neck
and intertrochanteric fracture, and high BR for femoral neck fracture
[11]. In this study, SM increased and BR decreased in the zoledronic
acid group, showing that zoledronic acid treatment improved hip
fracture-related parameters. Only at the femoral neck, no significant dif-
ferences in BR were noted between the zoledronic acid and placebo
group, but BR was significantly lower in the zoledronic acid group rela-
tive to baseline at both 12 and 24 months. The data presented above
suggest that zoledronic acid may reduce the risk of the occurrence of
hip fractures in Japanese osteoporotic patients.
The results of the present study are explorative and we hope to val-
idate them in future larger studies.
This study has two limitations. One is derived from the analysis
using CT, and the other is derived from the small number of subjects.
This study used the global BMD-based threshold of QCT-Pro as the anal-
ysis program, and the BMD value of each slice measured with the refer-
ence phantom showed good reproducibility (b0.1%). Since the cortical
bone in the superior part of the femoral neck is remarkably thin, and
there might be a partial volume effect in this part, the slice thickness
was set as thin as possible (0.500–0.625 mm) to minimize the effect.
Another limitation of this studywas that the number of subjects was
small and not representative of all subjects who receive zoledronic acid
treatment, because the subjects had to meet the inclusion criteria pre-
scribed in the protocol, and the medical institutions had to meet the
condition of being equipped with an MDCT scanner capable of certain
functions. In the future, it will be necessary to confirm the effect of zole-
dronic acid on the prevention of hip fractures in Japanese women.
In conclusion, once-yearly zoledronic acid treatment increased BMD
at all femoral sites, including the femoral neck, intertrochanteric region,
and shaft, and improved cortical bone geometry and CT-derived bone
biomechanical parameters in this study. Zoledronic acid may inhibit
hip fractures in Japanese osteoporotic patients.
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